[Viral conjunctivitis as the first sign of COVID-19 infection (clinical observation)].

The article presents a case of complicated viral conjunctivitis. Conjunctivitis was the initial sign of the new coronavirus infection (COVID-19) in the patient. The disease had a fairly long course and led to symmetrical scarring in the form of partial external symblepharon and dry eye syndrome.

[Use of macular lenses in patients with age-related macular degeneration].

The review presents the characteristics and results of clinical studies on implantation of different types of macular lenses (IOL-VIP system, Lipschitz Macular Implant (LMI), Fresnel Prism Intraocular, IOL AMD) installed in the capsular bag after phacoemulsification in patients with age-related macular degeneration (AMD). The literature review shows that up to now, the data on implantation of these lenses was contradictory and generally based only on short-term results. There are quite strict criteria for the selection of patients to evaluate the maximum possible postoperative visual rehabilitation of patients using special programs, the effectiveness of which largely depends on their commitment to postoperative, sometimes long-term treatment.

Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.

A comparison of the effects of the 6-(2-chloro-6-fluorobenzyl)-2-(alkylthio)pyrimidin-4(3H)-ones (2-Cl-6-F-S-DABOs) 7-12 and the related 6-(2,6-difluorobenzyl) counterparts 13-15 in HIV-1 infected cells and in the HIV-1 reverse transcriptase (RT) assays is here described. The new 2-Cl-6-F-S-DABOs showed up to picomolar activity against wt HIV-1. Against clinically relevant HIV-1 mutants and in enzyme assays, the simultaneous C5(methyl)/C6(methyl/ethyl) substitution in the 2-Cl-6-F- and 2,6-F2-benzyl series furnished compounds with the highest, wide-spectrum inhibitory activity against HIV-1.

[Results of fistulizing and Ahmed valve surgery for treatment of refractory glaucoma].

Surgical results of 76 patients (76 eyes) aged 25-79 years with secondary refractory glaucoma were analyzed. The best hypotensive effect and visual functions integrity were achieved with Ahmed valve implantation (86.7% and 83.

[Anti-VEGF-agents in treatment of neovascular glaucoma].

Neovascular glaucoma (NVG) is one of the most severe form of refractory glaucoma. Vascular endothelial growth factor (VEGF) is one of the strongest promoters of angiogenesis and was found to be the main neovascularization regulator. The use of anti-VEGF-agents is a rational option because in the majority of cases it allows to reach disappearance or reduction of neovascularization, that significantly reduces the risk of complications in following surgery or laser treatment of NVG.